These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7869772)

  • 1. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow.
    van Rhee F; Marks DI; Lin F; Szydlo RM; Hochhaus A; Treleaven J; Delord C; Cross NC; Goldman JM
    Leukemia; 1995 Feb; 9(2):329-35. PubMed ID: 7869772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
    Guo JQ; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus RB
    Leukemia; 2002 Dec; 16(12):2447-53. PubMed ID: 12454751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome].
    Román J; Castillejo JA; Jiménez A; Maldonado J; Torres A
    Med Clin (Barc); 1999 Dec; 113(20):779-82. PubMed ID: 10680143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia.
    Tuszynski A; Dhut S; Young BD; Lister TA; Rohatiner AZ; Amess JA; Chaplin T; Dorey E; Gibbons B
    Leukemia; 1993 Oct; 7(10):1504-8. PubMed ID: 8412311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
    Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
    Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
    Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay.
    Yokota H; Tsuno NH; Tanaka Y; Fukui T; Kitamura K; Hirai H; Osumi K; Itou N; Satoh H; Okabe M; Nakahara K
    Leukemia; 2002 Jun; 16(6):1167-75. PubMed ID: 12040449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P190-type bcr/abl expressed in myeloid colonies in a patient with Ph1-positive acute lymphoblastic leukemia.
    Sadamura S; Umemura T; Hirata J; Takahira H; Yufu Y; Abe Y; Nishimura J; Nawata H
    Leukemia; 1992 Aug; 6(8):791-5. PubMed ID: 1640730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sequential analysis of p210- and p190-bcr-abl by RT-PCR after allogeneic bone marrow transplantation for p210/p190-bcr-abl double positive acute lymphoblastic leukemia].
    Fujimaki K; Maruta A; Yoshida M; Yamazaki E; Motomura S; Kodama F; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2001 Feb; 42(2):89-93. PubMed ID: 11280922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia.
    Kohler S; Galili N; Sklar JL; Donlon TA; Blume KG; Cleary ML
    Leukemia; 1990 Aug; 4(8):541-7. PubMed ID: 2201832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
    Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
    Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymerase chain reaction: a method for monitoring tumor cell purge by long-term culture in BCR/ABL positive acute lymphoblastic leukemia.
    Fabrega S; Laporte JP; Giarratana MC; Douay L; Fouillard L; Da WM; Perrot C; Barbu V; Gorin NC
    Bone Marrow Transplant; 1993 Feb; 11(2):169-73. PubMed ID: 8435666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K; Tabayashi T; Yamada K; Takeuchi M
    Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
    Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman JM; Cross NC
    Leukemia; 1997 Apr; 11 Suppl 3():541-4. PubMed ID: 9209451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
    Estrov Z; Talpaz M; Zipf TF; Kantarjian HM; Ku S; Ouspenskaia MV; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
    J Cell Physiol; 1996 Mar; 166(3):618-30. PubMed ID: 8600166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
    Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
    Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undifferentiated immunophenotypes and not expression of BCR-ABL can be associated in adult Mestizo Mexican patients with ALL.
    Vázquez-Franco JE; Reyes-Maldonado E; Montiel-Cervantes LA; Lezama RA
    Rev Invest Clin; 2012; 64(1):32-9. PubMed ID: 22690527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.